XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Option Plan
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock Option Plan Stock Option Plan
2019 Incentive Award Plan
In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. As of March 31, 2021, 1,391,215 shares remained available for future awards.
2019 Employee Stock Purchase Plan
In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of March 31, 2021, 345,493 shares remained available for issuance under the ESPP.
Stock Options
Stock option activity under the Company's 2019 Plan is set forth below:
 
Number of
Options
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding, December 31, 20201,975,761 $11.81 8.71$6,750 
Granted88,750 $18.20 
Exercised(3,381)$12.94 
Forfeited(17,197)$12.16 
Expired(2,353)$29.08 
Outstanding, March 31, 2021
2,041,580 $12.06 8.54$13,247 
Vested and expected to vest, March 31, 2021
2,041,580 $12.06 8.54$13,247 
Options exercisable, March 31, 2021
665,878 $9.52 8.06$6,013 
The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of March 31, 2021, total unrecognized compensation cost related to option awards was $8.8 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.6 years.
Restricted Stock Units
Restricted stock unit activity under the Company's 2019 Plan is set forth below:
Number of
Shares
Weighted-
Average
Grant Date Fair Value
Aggregate
Intrinsic
Value
Outstanding, December 31, 2020— $— $— 
Awards granted185,000 $18.20 
Awards released— $— 
Awards canceled— $— 
Outstanding, March 31, 2021
185,000 $18.20 $3,238 
During the quarter ended March 31, 2021, the Company awarded 185,000 RSUs at a weighted-average grant date fair value per share of $18.20 to certain employees, all of which are outstanding and unvested as of March 31, 2021. As of March 31, 2021, total unrecognized compensation cost related to restricted stock units was $3.3 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.9 years.
Stock-Based Compensation Expense
Stock Options
The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:
 
 Three Months Ended March 31,
 20212020
Expected volatility
84%
47%-50%
Risk-free interest rate
0.8%
0.6%-1.7%
Dividend yield
Expected term (in years)
6.08
6.08
Employee Stock Purchase Plan
The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:
 Three Months Ended March 31,
 20212020
Expected volatility60%58%
Risk-free interest rate0.1%1.1%
Dividend yield
Expected term (in years)0.500.50
Stock-based compensation expense for the ESPP was immaterial for the three months ended March 31, 2021 and 2020. As of March 31, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.4 years.
Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):
 
 Three Months Ended March 31,
 20212020
Cost of revenue$11 $
Selling, general and administrative791 422 
Research and development110 
Total$912 $431